Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

First commercial procedures performed with Zenflow Spring for BPH

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at urologytimes.com →

◆ Verified

Fusion42 · 9 September 2026 · Fusion42 review

The Zenflow Spring Implant and Delivery System has begun commercial use in the US for treating symptomatic BPH following FDA approval. Initial procedures at four centers show significant symptom improvement and a favourable safety profile up to 12 months.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Zenflow’s US rollout opens a new treatment route for BPH patients that avoids catheter discomfort and rapid symptom relief. If you build urology devices, clinical centres now have a proven option to adopt or compete against.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Medtechbphurologymedtechdevice-approvalzenflow